Rotigotine transdermal system: Developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome

Annals of the New York Academy of Sciences

Volumn 1329, Issue 1, 2014, Pages 45-66

  Benitez, Arturo ^a   Edens, Heather ^a   Fishman, Jesse ^a   Moran, Kimberly ^a   Asgharnejad, Mahnaz ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Dopamine agonists; Neurodegenerative disease; Parkinson's disease; Restless legs syndrome; Rotigotine

Indexed keywords

PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; DOPAMINE RECEPTOR STIMULATING AGENT; TETRALIN DERIVATIVE; THIOPHENE DERIVATIVE;

APPLICATION SITE REACTION; ARTICLE; BACKACHE; COMPULSION; CONSTIPATION; DAYTIME SOMNOLENCE; DIZZINESS; DOPAMINERGIC ACTIVITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; HYPERSEXUALITY; IMPULSE CONTROL DISORDER; INSOMNIA; KIDNEY CLEARANCE; LIBIDO DISORDER; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PARKINSON DISEASE; PERIPHERAL EDEMA; PRURITUS; RESTLESS LEGS SYNDROME; RHINOPHARYNGITIS; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; VOMITING; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; INTRADERMAL DRUG ADMINISTRATION; TRENDS;

ADMINISTRATION, CUTANEOUS; CLINICAL TRIALS AS TOPIC; DOPAMINE AGONISTS; DRUG DELIVERY SYSTEMS; HUMANS; PARKINSON DISEASE; RESTLESS LEGS SYNDROME; TETRAHYDRONAPHTHALENES; THIOPHENES;

EID: 84910623907     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12508     Document Type: Article

References (118)

1. Trenkwalder, C. & W. Paulus. 2010. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat. Rev. Neurol. 6: 337-346.
2. Lees, A.J. et al. 2009. Parkinson's disease. Lancet 373: 2055-2066.
3. Kowal, S.L. et al. 2013. The current and projected economic burden of Parkinson's disease in the United States. Mov. Disord. 28: 311-318.
4. Olanow, C.W. et al. 2009. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology 72: S1-136.
5. National Institute of Neurological Disorders and Stroke. 2004. Parkinson's disease backgrounder. March 25, 2014.http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_disease_backgrounder.htm.
6. Wirdefeldt, K. et al. 2011. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 26(Suppl 1): S1-S58.
7. National Institute of Neurological Disorders and Stroke. 2010. Restless legs syndrome fact sheet. March 25, 2014. http://www.ninds.nih.gov/disorders/restless_legs/detail_restless_legs.htm.
8. Innes, K.E. et al. 2011. Prevalence of restless legs syndrome in North American and Western European populations: a systematic review. Sleep Med. 12: 623-634.
9. Ohayon, M.M. et al. 2012. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med. Rev. 16: 283-295.
10. Allen, R.P. et al. 2005. Restless legs syndrome prevalence and impact: REST general population study. Arch. Intern. Med. 165: 1286-1292.
11. Antonini, A. et al. 2010. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders. Funct. Neurol. 25: 21-25.
12. Elshoff, J.P. et al. 2012. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin. Ther. 34: 966-978.
13. Barone, P. et al. 2009. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov. Disord. 24: 1641-1649.
14. Rana, A.Q. et al. 2013. A cross-sectional study investigating clinical predictors and physical experiences of pain in Parkinson's disease. Funct. Neurol. 28: 297-304.
15. Seppi, K. et al. 2011. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Mov. Disord. 26(Suppl 3): S42-80.
16. Pfeiffer, R.F. 2011. Gastrointestinal dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 17: 10-15.
17. Antonini, A. et al. 2012. The progression of non-motor symptoms in Parkinson's disease and their contribution to motor disability and quality of life. J. Neurol. 259: 2621-2631.
18. Breen, K.C. & G. Drutyte 2013. Non-motor symptoms of Parkinson's disease: the patient's perspective. J. Neural Transm. 120: 531-535.
19. Duncan, G.W. et al. 2014. Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms. Mov. Disord. 29: 195-202.
20. Martinez-Martin, P. et al. 2011. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease. Mov. Disord. 26: 399-406.
21. Santos-Garcia, D. & R. de la Fuente-Fernández. 2013. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease. J. Neurol. Sci. 332: 136-140.
22. Song, W. et al. 2014. The impact of non-motor symptoms on the health-related Quality of Life of Parkinson's disease patients from Southwest China. Parkinsonism Relat. Disord. 20: 149-152.
23. Weerkamp, N.J. et al. 2013. Nonmotor symptoms in nursing home residents with Parkinson's disease: prevalence and effect on quality of life. J. Am. Geriatr. Soc. 61: 1714-1721.
24. Jenner, P. et al. 2011. Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression. J. Neural Transm. 118: 1691-1702.
25. Lv, Q. & B. Zhang. 2013. Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease. Neurosci. Bull. 29: 661-669.
26. International Restless Legs Syndrome Study Group. 2012. 2012 Revised IRLSSG diagnostic criteria for RLS. Accessed March 25, 2014. http://irlssg.org/diagnostic-criteria/.
27. Hening, W. et al. 2004. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med. 5: 237-246.
28. Tzonova, D. et al. 2012. Breakthrough symptoms during the daytime in patients with restless legs syndrome (Willis-Ekbom disease). Sleep Med. 13: 151-155.
29. Giannaki, C.D. et al. 2013. Epidemiology, impact, and treatment options of restless legs syndrome in end-stage renal disease patients: an evidence-based review. Kidney Int. 85: 1275-1282.
30. Allen, R.P. & C.J. Earley. 2007. The role of iron in restless legs syndrome. Mov. Disord. 22(Suppl 18): S440-S448.
31. Brand, S. et al. 2013. Patients suffering from restless legs syndrome have low internal locus of control and poor psychological functioning compared to healthy controls. Neuropsychobiology 68: 51-58.
32. Cho, Y.W. et al. 2012. Assessing health-related quality of life in patients with restless legs syndrome in Korea: comparison with other chronic medical diseases. Sleep Med. 13: 1158-1163.
33. Dodel, R. et al. 2010. Health economic burden of patients with restless legs syndrome in a German ambulatory setting. Pharmacoeconomics 28: 381-393.
34. Salas, R.E. & A.B. Kwan. 2012. The real burden of restless legs syndrome: clinical and economic outcomes. Am. J. Manag. Care 18: S207-212.
35. Scholz, H. et al. 2011. Psychological distress of patients suffering from restless legs syndrome: a cross-sectional study. Health Qual. Life Outcomes 9: 73.
36. Wesström, J. et al. 2010. Health-related quality of life and restless legs syndrome among women in Sweden. Psychiatry Clin. Neurosci. 64: 574-579.
37. Ferini-Strambi, L. et al. 2013. The relationship among restless legs syndrome (Willis-Ekbom Disease), hypertension, cardiovascular disease, and cerebrovascular disease. J. Neurol. 261: 1051-1068.
38. Siddiqui, F. et al. 2007. Rise of blood pressure with periodic limb movements in sleep and wakefulness. Clin. Neurophysiol. 118: 1923-1930.
39. Jenner, P. 2005. A novel dopamine agonist for the transdermal treatment of Parkinson's disease. Neurology 65(Suppl 1): S3-S5.
40. Horn, A.S. et al. 1984. N-0434, a very potent and specific new D-2 dopamine receptor agonist. Eur. J. Pharmacol. 99: 125-126.
41. Van der Weide, J. et al. 1986. Pharmacological profiles of three new, potent and selective dopamine receptor agonists: N-0434, N-0437 and N-0734. Eur. J. Pharmacol. 125: 273-282.
42. Belluzzi, J.D. et al. 1994. N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease. Mov. Disord. 9: 147-154.
43. Loschmann, P.A. et al. 1989. Stereoselective reversal of MPTP-induced parkinsonism in the marmoset after dermal application of N-0437. Eur. J. Pharmacol. 166: 373-380.
44. Scheller, D. et al. 2009. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn. Schmiedebergs Arch. Pharmacol. 379: 73-86.
45. Waters, C. 2013. The development of the rotigotine transdermal patch: a historical perspective. Neurol. Clin. 31: S37-50.
46. Millan, M.J. et al. 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther. 303: 791-804.
47. Nicholson, S.L. & J.M. Brotchie. 2002. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Eur. J. Neurol. 9(Suppl 3): 1-6.
48. Ohno, Y. 2011. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease. CNS Neurosci. Ther. 17: 58-65.
49. Chaudhuri, K.R. & A. H. Schapira. 2009. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol. 8: 464-474.
50. Barone, P. 2010. Neurotransmission in Parkinson's disease: beyond dopamine. Eur. J. Neurol. 17: 364-376.
51. Fox, S.H. et al. 2008. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol. 7: 927-938.
52. Remy, P. et al. 2005. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 128: 1314-1322.
53. Swart, P.J. & R.A. de Zeeuw. 1992. Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats. Pharmazie 47: 613-615.
54. Swart, P.J. & R.A. de Zeeuw. 1993. Pharmacokinetics of the dopamine D2 agonist S(-)-2-(N-propyl-N-2-thienylethylamino)-5-hydroxytetralin in freely moving rats. J. Pharm. Sci. 82: 200-203.
55. Schmidt, W.J. et al. 2008. Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. J. Neural Transm. 115: 1385-1392.
56. Stockwell, K.A. et al. 2009. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction. Exp. Neurol. 219: 533-542.
57. UCB Pharma. 2013. Neupro® (rotigotine transdermal system) (U.S. prescribing information). March 25, 2014. Revised 2013. www.accessdata.fda.gov/drugsatfda_docs/label/.../021829s002lbl.pdf.
58. Chaudhuri, K.R. 2008. Crystallisation within transdermal rotigotine patch: is there cause for concern? Expert Opin. Drug Deliv. 5: 1169-1171.
59. Elshoff, J.P. et al. 2013. Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations. Curr. Med. Res. Opin. 29: 1657-1662.
60. UCB Pharma. 2013. Annex 1: Summary of Product Characteristics (Neupro® (rotigotine transdermal patch)). March 25, 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000626/WC500026397.pdf.
61. Cawello, W. et al. 2009. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab. Dispos. 37: 2055-2060.
62. Cawello, W. et al. 2007. Transdermal administration of radiolabelled (14C)rotigotine by a patch formulation: a mass balance trial. Clin. Pharmacokinet. 46: 851-857.
63. Malik, M. et al. 2008. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin. Pharmacol. Ther. 84: 595-603.
64. Hansen, K. et al. 2005. Low drug-drug interaction potential of rotigotine. J. Clin. Pharmacol. 45: 1091.
65. Elshoff, J. et al. 2014. No influence on the CYP2C19-selective inhibitor omeprazle on the pharmacokinetics of the dopamine receptor agonist rotigotine. Clin. Pharmacol. Drug Dev. 3: 187-193.
66. Braun, M. et al. 2009. Influence of domperidone on pharmacokinetics, safety and tolerability of the dopamine agonist rotigotine. Br. J. Clin. Pharmacol. 67: 209-215.
67. Braun, M. et al. 2009. Lack of pharmacokinetic interactions between transdermal rotigotine and oral levodopa/carbidopa. J. Clin. Pharmacol. 49: 1047-1055.
68. Araujo, S.M. et al. 2010. Restless legs syndrome in end-stage renal disease: clinical characteristics and associated comorbidities. Sleep Med. 11: 785-790.
69. Gigli, G.L. et al. 2004. Restless legs syndrome in end-stage renal disease. Sleep Med. 5: 309-315.
70. Lin, C.H. et al. 2013. Restless legs syndrome in end-stage renal disease: a multicenter study in Taiwan. Eur. J. Neurol. 20: 1025-1031.
71. Takaki, J. et al. 2003. Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am. J. Kidney Dis. 41: 833-839.
72. Cawello, W. et al. 2012. Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function. Br. J. Clin. Pharmacol. 73: 46-54.
73. Cawello, W. et al. 2013. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine. Eur. J. Drug Metab. Pharmacokinet. Sep 20. (Epub ahead of print).
74. Braun, M. et al. 2009. Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptive. Br. J. Clin. Pharmacol. 68: 386-394.
75. Elmer, L.W. et al. 2012. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson's disease: a prospective, open-label extension study. Parkinsonism Relat. Disord. 18: 488-493.
76. Giladi, N. et al. 2007. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov. Disord. 22: 2398-2404.
77. Giladi, N. et al. 2013. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson's disease. J. Neural Transm. 120: 1321-1329.
78. LeWitt, P.A. et al. 2012. Rotigotine transdermal system for long-term treatment of patients with advanced Parkinson's disease: results of two open-label extension studies, CLEOPATRA-PD and PREFER. J. Neural Transm. 120: 1069-1081.
79. LeWitt, P.A. et al. 2007. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68: 1262-1267.
80. Poewe, W.H. et al. 2007. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 6: 513-520.
81. The Parkinson Study Group. 2003. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch. Neurol. 60: 1721-1728.
82. Trenkwalder, C. et al. 2012. Rotigotine transdermal system for the management of motor function and sleep disturbances in Parkinson's disease: Results from a 1-year, open-label extension of the RECOVER study. Basal Ganglia 2: 79-85.
83. Trenkwalder, C. et al. 2011. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov. Disord. 26: 90-99.
84. Watts, R.L. et al. 2007. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68: 272-276.
85. Pham D.Q. & A. Nogid 2008. Rotigotine transdermal system for the treatment of Parkinson's disease. Clin. Ther. 30: 813-824.
86. Oertel, W. et al. 2013. Treatment of patients with early and advanced Parkinson's disease with rotigotine transdermal system: age-relationship to safety and tolerability. Parkinsonism Relat. Disord. 19: 37-42.
87. Trenkwalder, C. et al. 2011. Parkinson's disease sleep scale-validation of the revised version PDSS-2. Mov. Disord. 26: 644-652.
88. Trenkwalder, C. et al. 2008. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 7: 595-604.
89. Hening, W.A. et al. 2010. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov. Disord. 25: 1675-1683.
90. Bauer, A. et al. 2013. The effect of rotigotine transdermal system on nocturnal systolic blood pressure elevations associated with periodic leg movements in patients with restless legs syndrome (abstract). J. Clin. Hyperten. 15(Suppl 1): 12.
91. Beneš, H. et al. 2012. Augmentation in the treatment of restless legs syndrome with transdermal rotigotine. Sleep Med. 13: 589-597.
92. Dohin, E. et al. 2013. Safety and efficacy of rotigotine transdermal patch in patients with restless legs syndrome: a post-hoc analysis of patients taking 1 - 3 mg/24 h for up to 5 years. Expert Opin. Pharmacother. 14: 15-25.
93. Oertel, W. et al. 2011. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 10: 710-720.
94. Oertel, W.H. et al. 2008. Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind, placebo-controlled, six-week dose-finding trial in Europe. Sleep Med. 9: 228-239.
95. Oertel, W.H. et al. 2010. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 11: 848-856.
96. García-Borreguero, D. & A.M. Williams 2010. Dopaminergic augmentation of restless legs syndrome. Sleep Med. Rev. 14: 339-346.
97. García-Borreguero, D. et al. 2007. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 8: 520-530.
98. Innes, K.E. et al. 2011. Restless legs syndrome and conditions associated with metabolic dysregulation, sympathoadrenal dysfunction, and cardiovascular disease risk: a systematic review. Sleep Med. Rev. 16: 309-339.
99. Hassan, A. et al. 2011. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies. Parkinsonism Relat. Disord. 17: 260-264.
100. Kelley, B.J. et al. 2012. Dopamine agonists and pathologic behaviors. Parkinsons Dis. 2012: 603631.
101. Voon, V. & S.H. Fox. 2007. Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch. Neurol. 64: 1089-1096.
102. Weintraub, D. et al. 2010. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch. Neurol. 67: 589-595.
103. Zesiewicz, T.A. & P. Martinez-Martin. 2013. Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview. Expert Rev. Neurother. 13: 1329-1342.
104. Garcia-Ruiz, P.J. et al. 2014. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J. Neurol. Neurosurg. Psychiatry.
105. Voon, V. et al. 2011. Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome. BMC Neurol. 7 11: 117.
106. Wingo, T.S. et al. 2009. Impulse control disorders arising in 3 patients treated with rotigotine. Clin. Neuropharmacol. 32: 59-62.
107. Cornelius, J.R. et al. 2010. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 33: 81-87.
108. Schreglmann, S.R. et al. 2012. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat. Disord. 18: 207-209.
109. LeWitt, P.A. et al. 2007. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin. Neuropharmacol. 30: 256-265.
110. Kim, H.J. et al. 2011. Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurol. 11: 100.
111. Stiasny-Kolster, K. et al. 2013. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany. Sleep Med. 14: 475-481.
112. Senek, M. & D. Nyholm. 2014. Continuous drug delivery in Parkinson's disease. CNS Drugs 28: 19-27.
113. Jenner, P. 2004. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 62: S47-55.
114. Chaudhuri, K.R. et al. 2013. Motor and nonmotor complications in Parkinson's disease: an argument for continuous drug delivery? J. Neural Transm. 120: 1305-1320.
115. Ahlskog, J.E. 2007. Beating a dead horse: dopamine and Parkinson disease. Neurology 69: 1701-1711.
116. Jenner, P. 2009. From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl 4): S18-23.
117. Rascol, O. & S. Perez-Lloret. 2009. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin. Pharmacother. 10: 677-691.
118. Ghys, L. et al. 2011. Effect of rotigotine on sleep and quality of life in Parkinson's disease patients: post hoc analysis of RECOVER patients who were symptomatic at baseline. Expert Opin. Pharmacother. 12: 1985-1998.